Ruisinger and her colleagues mounted a study in an attempt to test the efficacy of once-a-week rosuvastatin on the lipid profile in patients with previous adverse events presumably secondary to a statin drug. The once-a-week schedule was tolerated by 74% of the patients with doses ranging from 2.5...